A Phase 4 interventional study of valsartan/amlodipine in Primary Hypertension, sponsored by Novartis. Completed at 1 site in Egypt. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing valsartan in Essential Hypertension — 2 open to participants now, 2 under way, 1 of them phase 3. Valsartan · Essential Hypertension.
Among the 10 studies testing valsartan in Essential Hypertension, this one is the 8th largest by planned enrollment, is one of 2 that started in 2009, is one of 4 in phase 4, and was the 5th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →2 of the 10 studies testing valsartan in Essential Hypertension are open now, in 1 country. Recruiting first, the newest first:
Shandong New Time Pharmaceutical Co., LTD · Sites in China
Ages 6–17
Sichuan Academy of Medical Sciences · Sites in China
Ages 18+
By country, each count listing its studies:
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 392 across the 10 interventional studies. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 7 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
27 studies in Essential Hypertension by Novartis: none open now, none under way, none of them phase 3. Of 27 finished, 19 (70%) have results posted.
Among the 27 studies in Essential Hypertension by Novartis, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 4, and was the 19th registered.
Novartis’s Essential Hypertension studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing valsartan in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to assess the efficacy of the fixed combination of Valsartan and Amlodipine in hypertensive patients uncontrolled by monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
valsartan/amlodipine
Drug: valsartan/amlodipine
Drug pages: Valsartan · Amlodipine
160/10 mg
Hypertension in patients that will be controlled on each concentration and those that will switch to the higher concentration (160/10)
Time frame: 4 weeks
Hypertension of patients that were previously controlled on (160/5) and those that were uncontrolled and switched to the higher concentration (160/10) after 4 weeks on (160/5) concentration.
Time frame: 8 weeks
Safety and Tolerability of the Trial Medication
Time frame: 8 weeks
The incidence of Edema
Time frame: 8 weeks
The record gives a start of Feb 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Amlodipine